Acquisition by Hill Linda A of 102225 shares of Relay Therapeutics at 6.79 subject to Rule 16b-3
| RLAY Stock | USD 6.20 0.06 0.98% |
Slightly above 50% of Relay Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Relay Therapeutics suggests that some traders are interested. Relay Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Relay Therapeutics' earnings reports, geopolitical events, and overall market trends.
Relay |
Filed transaction by Relay Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Relay Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Relay Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Relay Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Relay Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Relay Therapeutics Fundamental Analysis
We analyze Relay Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relay Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relay Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Relay Therapeutics is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Relay Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Relay Therapeutics stock to make a market-neutral strategy. Peer analysis of Relay Therapeutics could also be used in its relative valuation, which is a method of valuing Relay Therapeutics by comparing valuation metrics with similar companies.
Peers
Relay Therapeutics Related Equities
| STOK | Stoke Therapeutics | 4.60 | ||||
| APLS | Apellis Pharmaceuticals | 4.31 | ||||
| DAWN | Day One | 4.00 | ||||
| BDTX | Black Diamond | 3.46 | ||||
| TERN | Terns Pharmaceuticals | 3.40 | ||||
| CGEM | Cullinan Oncology | 2.82 | ||||
| EWTX | Edgewise Therapeutics | 2.68 | ||||
| FHTX | Foghorn Therapeutics | 2.63 | ||||
| AMLX | Amylyx Pharmaceuticals | 2.45 | ||||
| NRIX | Nurix Therapeutics | 0.37 | ||||
| CCCC | C4 Therapeutics | 0.33 | ||||
| BPMC | Blueprint Medicines | 0.55 | ||||
| MLYS | Mineralys Therapeutics, | 0.85 | ||||
| PLRX | Pliant Therapeutics | 1.25 | ||||
| IPSC | Century Therapeutics | 1.37 | ||||
| ARVN | Arvinas | 2.20 | ||||
| GLUE | Monte Rosa | 2.83 |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.